Today: 29 June 2026
NAB share price falls 1.3% as oil shock and RBA risk hit National Australia Bank stock
19 March 2026
1 min read

NAB share price falls 1.3% as oil shock and RBA risk hit National Australia Bank stock

SYDNEY, March 20, 2026, 09:11 AEDT

National Australia Bank Ltd dropped 1.29% to finish at A$46.62 on Thursday, after a new oil spike and a broader move out of risk assets sent investors fleeing stocks. Brent crude surged past $119 a barrel at one point, shaking global markets.

Why does this matter? NAB’s got a front-row seat in Australia’s rate picture. On Tuesday, the Reserve Bank of Australia bumped the cash rate up by 25 basis points to 4.10%—a 5-4 split. Policymakers flagged a “material risk” that inflation could stick above target for longer. That dynamic can pad bank margins—boosting what they collect on loans compared to funding costs—even as it increases strain for borrowers. Reserve Bank of Australia

Thursday’s labour data left things unsettled. The economy added 48,900 jobs in February, yet the jobless rate edged up to 4.3% and hours worked slipped 0.2%. “Leaned slightly weaker on the headline measures,” said AMP economist My Bui, though markets still priced in about a 57% chance of a May hike. Reuters

NAB chief economist Sally Auld pointed out that the “most important take away” from Tuesday’s move was the central bank’s more hawkish tone on persistent inflation. NAB’s forecast for a further 25-basis-point hike in May stays in place. That leaves the stock straddling higher lending profits and the downside of softer growth. NAB News

NAB isn’t waiting. The bank announced it will hike variable home-loan rates by 25 basis points starting March 27. Group executive Ana Marinkovic called another rise “challenging for many Australians” already struggling with cost-of-living pressures. NAB News

Sentiment soured late in the day. According to Michael Arone, chief investment strategist at State Street Investment Management, the market’s been “fairly binary” during bouts of higher oil and inflation expectations—investors don’t hesitate to retreat from stocks when energy prices spike. Reuters

But there’s still a risk the trade reverses. The RBA’s Financial Stability Review, out Thursday, flagged that global financial system risks have gone up. Some borrowers will run into bigger hurdles. Lenders, the central bank warned, need to stick to tougher lending standards, despite Australia’s banks being in a strong position if a sharper downturn hits.

Competitive pressures remain part of the equation. As Morningstar points out, NAB stands out as the big four’s most business-oriented lender and holds the number two spot for market capitalization in Australia. As of Thursday’s close, Commonwealth Bank finished at A$177.36, with ANZ at A$37.02.

Thursday’s drop doesn’t exist in a vacuum. Just last month, Reuters noted that NAB surged to a record high after reporting a 16% jump in first-quarter cash earnings, driven by gains in business and home loans. The latest decline came with that stronger performance still fresh in the background.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Neurocrine Biosciences (NBIX) Gains as Strong Earnings Forecasts Boost Stock
    June 29, 2026, 5:49 AM EDT. Neurocrine Biosciences (NBIX) has emerged as a robust biotech performer with strong earnings momentum driven by its flagship treatment INGREZZA, which treats movement disorders. Analysts have sharply raised earnings per share (EPS) estimates for NBIX across upcoming quarters and fiscal years, reflecting increased confidence in the stock. INGREZZA's sales reached $2.86 billion in 2025, up 22% year-over-year, with projected growth continuing in 2026. The company also benefits from growing physician adoption and expanding patient awareness. Rising earnings forecasts, driven by strong operational performance and a broad consensus among analysts, have elevated NBIX to a Zacks Rank #1 (Strong Buy). Investors see Neurocrine's expanding portfolio and pipeline as key to sustaining growth beyond INGREZZA's success.

Latest articles

ServiceNow (NYSE:NOW) stock: $9 billion Friday jump puts contract base back in focus

ServiceNow (NYSE:NOW) stock: $9 billion Friday jump puts contract base back in focus

29 June 2026
ServiceNow (NYSE:NOW) surged 9.85% to $98.34 Friday, adding $9.1 billion in equity value—about 72% of its $12.64 billion Q1 current remaining performance obligations—as software stocks outperformed amid rotation out of AI names; the move comes ahead of a potential near-term bookings catalyst tied to price increases and legacy tier retirements, with short interest at 5.82% of float.
Nvidia holds $47 billion-per-point sway as Nasdaq tries for bounce

Nvidia holds $47 billion-per-point sway as Nasdaq tries for bounce

29 June 2026
Nvidia’s $4.7 trillion market value means every 1% stock move shifts $47 billion, putting massive index risk in focus as AI capex spending faces fresh scrutiny from new BIS data and rising China chip competition, with premarket gains tested by funding and substitution risks.
Bitcoin Price Slides Below $70,000 After Fed Warning, Oil Spike Rattle Crypto Stocks
Previous Story

Bitcoin Price Slides Below $70,000 After Fed Warning, Oil Spike Rattle Crypto Stocks

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Next Story

US Stock Market Today: Live Updates 24.03.2026

Go toTop